相关实验视频
Updated: Jul 21, 2025

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
对心力衰竭和心肌病的基因治疗
Alessia Argirò1, Jeffrey Ding2, Eric Adler2
1Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
Revista espanola de cardiologia (English ed.)
|July 28, 2023
概括
使用基因替代或编辑的基因疗法为遗传性疾病提供了新的治疗方法,并正在研究诸如心肌病等心脏病的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 基因治疗包括替换或编辑有缺陷的基因以治疗疾病.
- 已有批准的治疗方法用于勒伯先天性黄斑症和脊柱肌肉缩.
- 新兴的研究重点是基因治疗在心脏病学中的应用.
研究的目的:
- 审查基因疗法机制,输送系统和风险.
- 总结当前的临床试验和基因疗法的未来目标.
- 强调基因疗法治疗心肌病的潜力.
主要方法:
- 对基因治疗策略的文献综述.
- 对基因传递系统和相关风险的分析.
- 检查正在进行的临床试验和研究趋势.
主要成果:
- 基因替代和基因编辑是关键的治疗策略.
- 采用了各种交付系统,每个都有特定的风险.
- 临床试验正在扩大,以心肌病为重点.
结论:
- 基因疗法在治疗遗传疾病方面具有重大前景.
- 进一步的研究对于在心脏病学中推进基因治疗至关重要.
- 心肌病是未来基因疗法发展的关键领域.
相关概念视频
Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16

